IDEXX Laboratories, Inc.

IDXX Healthcare Diagnostics & Research

IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024.

Revenue
+9.86%
EPS
+17.3%
Free cash flow
+17.6%
Total debt
−28.6%

Quarter to September 2026, against a year earlier

677.59 6.88 +1.03%
Market cap
$52.8B
P/E
44.8×
Fwd P/E
37.3×
Dividend yield
—
F-score
8/9
Altman Z
24.09
Beneish M
−2.50
Dividend safety
n/a

IDEXX Laboratories, Inc. 10-Q filed Nov 2, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 4:29 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Nov 3, 2025: 32 added · 44 removed · 46 modified; 1 with only figures updated; 1 moved without change